Centurion Wealth Management LLC lowered its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 1.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 6,422 shares of the company’s stock after selling 63 shares during the period. Centurion Wealth Management LLC’s holdings in Johnson & Johnson were worth $995,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also modified their holdings of JNJ. Summit X LLC boosted its stake in Johnson & Johnson by 14.6% in the first quarter. Summit X LLC now owns 3,701 shares of the company’s stock valued at $574,000 after acquiring an additional 471 shares during the last quarter. Cerro Pacific Wealth Advisors LLC boosted its stake in Johnson & Johnson by 10.6% in the first quarter. Cerro Pacific Wealth Advisors LLC now owns 14,948 shares of the company’s stock valued at $2,317,000 after acquiring an additional 1,436 shares during the last quarter. Delaney Dennis R boosted its stake in Johnson & Johnson by 0.3% in the first quarter. Delaney Dennis R now owns 26,591 shares of the company’s stock valued at $4,122,000 after acquiring an additional 70 shares during the last quarter. Moran Wealth Management LLC boosted its stake in Johnson & Johnson by 26.0% in the first quarter. Moran Wealth Management LLC now owns 216,379 shares of the company’s stock valued at $33,539,000 after acquiring an additional 44,619 shares during the last quarter. Finally, Gateway Wealth Partners LLC boosted its stake in Johnson & Johnson by 7.6% in the first quarter. Gateway Wealth Partners LLC now owns 6,293 shares of the company’s stock valued at $975,000 after acquiring an additional 443 shares during the last quarter. Institutional investors and hedge funds own 67.57% of the company’s stock.
Insider Buying and Selling
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 12,465 shares of the stock in a transaction on Monday, June 12th. The shares were sold at an average price of $160.00, for a total value of $1,994,400.00. Following the completion of the sale, the executive vice president now owns 65,934 shares in the company, valued at $10,549,440. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, EVP Kathryn E. Wengel sold 12,465 shares of the company’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $160.00, for a total value of $1,994,400.00. Following the sale, the executive vice president now directly owns 65,934 shares of the company’s stock, valued at approximately $10,549,440. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the transaction, the vice president now owns 102,696 shares of the company’s stock, valued at approximately $17,491,182.72. The disclosure for this sale can be found here. Over the last three months, insiders have sold 47,163 shares of company stock worth $7,928,856. Insiders own 0.20% of the company’s stock.
Wall Street Analysts Forecast Growth
Johnson & Johnson Stock Up 1.4 %
Johnson & Johnson stock opened at $166.25 on Friday. The company has a fifty day simple moving average of $166.68 and a 200 day simple moving average of $161.48. The company has a current ratio of 1.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 1-year low of $150.11 and a 1-year high of $181.04. The company has a market cap of $432.08 billion, a P/E ratio of 33.65, a price-to-earnings-growth ratio of 2.77 and a beta of 0.54.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its earnings results on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.62 by $0.18. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The business had revenue of $25.53 billion for the quarter, compared to the consensus estimate of $24.63 billion. During the same quarter in the previous year, the business earned $2.59 earnings per share. Johnson & Johnson’s quarterly revenue was up 6.3% on a year-over-year basis. Research analysts anticipate that Johnson & Johnson will post 10.75 earnings per share for the current fiscal year.
Johnson & Johnson Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Monday, August 28th will be issued a $1.19 dividend. This represents a $4.76 annualized dividend and a dividend yield of 2.86%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s payout ratio is presently 96.36%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
- Five stocks we like better than Johnson & Johnson
- What is the FTSE 100 index?
- 2 Stocks to Get You Ready for the Holiday Season
- Investing In Preferred Stock vs. Common Stock
- Profit Potential: 5 Undervalued Stocks With High Dividend Yields
- Retail Stocks Investing, Explained
- MarketBeat Week in Review – 8/21 – 8/25
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.